INF-y 1b Type of group
Sponsors
INTERMUNE PHARMACEUTICALS, INC.,
Early Phase 1
PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON SAFETY AND EFFECTIVENESS OF THE GAMMA-1B SUBCUTANEOUS INTERPHERE (IFN-Y 1B) IN COMBINATION WITH STANDARD ANTIFUNGAL THERAPY FOR THE TREATMENT OF ACUTE CRYTOCOCCAL MENINGITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).
Active, not recruitingPER-025-03
Updated: 2023-09-04
PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON SAFETY AND EFFECTIVENESS OF THE GAMMA-1B SUBCUTANEOUS INTERPHERE (IFN-Y 1B) IN COMBINATION WITH STANDARD ANTIFUNGAL THERAPY FOR THE TREATMENT OF ACUTE CRYTOCOCCAL MENINGITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).
Active, not recruitingPER-022-03
Updated: 2023-09-04